Literature DB >> 9813667

Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides.

S Simões1, V Slepushkin, R Gaspar, M C de Lima, N Düzgüneş.   

Abstract

Potential problems with the use of viral vectors for gene therapy necessitate the development of efficient nonviral vectors. The association of transferrin, or the pH-sensitive peptide GALA, with cationic liposomes composed of 1,2-dioleoyl-3-(trimethylammonium) propane and its equimolar mixture with dioleoylphosphatidylethanolamine, under conditions where the liposome/DNA complex is negatively charged, drastically increased luciferase expression from pCMVluc. The percentage of cells transfected, measured by beta-galactosidase expression, was also increased by about 10-fold. The zeta potential of the ternary complexes was lower than that of the liposome/DNA complexes. Transfection activity of positively charged complexes was also enhanced by association with transferrin, GALA or the influenza hemagglutinin N terminal peptide HA-2, but to a smaller extent compared with the negatively charged complexes. The enhancement of gene delivery by transferrin or GALA was not affected significantly by the presence of serum and did not cause significant cytotoxicity. Our results indicate that negatively charged ternary complexes of cationic liposomes, DNA and transferrin, or fusigenic peptides, can facilitate efficient transfection of cultured cells, and that they may alleviate the drawbacks of the use of highly positively charged complexes for gene delivery in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813667     DOI: 10.1038/sj.gt.3300674

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  21 in total

1.  Quantitative analysis of correlation between number of nuclear plasmids and gene expression activity after transfection with cationic liposomes.

Authors:  Rieko Tachibana; Hideyoshi Harashima; Naoko Ide; Sachiko Ukitsu; Yasuko Ohta; Norio Suzuki; Hiroshi Kikuchi; Yasuo Shinohara; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

2.  Use of collagen gel as a three-dimensional in vitro model to study electropermeabilization and gene electrotransfer.

Authors:  Sasa Haberl; Mojca Pavlin
Journal:  J Membr Biol       Date:  2010-07-18       Impact factor: 1.843

Review 3.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

4.  WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma.

Authors:  Santiago Saavedra-Alonso; Pablo Zapata-Benavides; Ana Karina Chavez-Escamilla; Edgar Manilla-Muñoz; Diana Elisa Zamora-Avila; Moisés Armides Franco-Molina; Cristina Rodriguez-Padilla
Journal:  Exp Ther Med       Date:  2016-10-27       Impact factor: 2.447

Review 5.  Functional peptides for siRNA delivery.

Authors:  Wanyi Tai; Xiaohu Gao
Journal:  Adv Drug Deliv Rev       Date:  2016-08-13       Impact factor: 15.470

6.  Biotinylated photocleavable polyethylenimine: capture and triggered release of nucleic acids from solid supports.

Authors:  Rachel G Handwerger; Scott L Diamond
Journal:  Bioconjug Chem       Date:  2007-04-14       Impact factor: 4.774

7.  Two African swine fever virus proteins derived from a common precursor exhibit different nucleocytoplasmic transport activities.

Authors:  A Eulálio; I Nunes-Correia; A L Carvalho; C Faro; V Citovsky; S Simões; M C Pedroso de Lima
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Cationic lipid-coated magnetic nanoparticles associated with transferrin for gene delivery.

Authors:  Xiaogang Pan; Jingjiao Guan; Jung-Woo Yoo; Arthur J Epstein; L James Lee; Robert J Lee
Journal:  Int J Pharm       Date:  2008-03-04       Impact factor: 5.875

Review 9.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

10.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.